We previously showed that circulating anti-TERT CD4 T cell response is a surrogate marker of the host’s antitumor Th1 immunity and that the presence or induction of circulating anti-TERT CD4 T cell response was associated with a good prognosis in several cancers such as renal carcinoma, anal carcinoma, and NSCLC [33–35, 37, 38]. This evidence concerns the gene CD4 and cancer.